AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Inhibrx Biosciences Inc.
Video analysis: INBX
All videosNo video analysis for this stock yet. Request one from our team.
News: INBX
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarcoma progression and strong response rates in colorectal and Ewing sarcoma cohorts, fueling prior share price surges. INBRX-106, combined with Keytruda, showed a 48.3% cORR in head and neck cancer in data shared yesterday, with pronounced efficacy in HPV+ patients, but market response remains muted.
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx Biosciences Inc. (NASDAQ:INBX) announced primary endpoint results from the randomized Phase 2 portion of its HexAgon study.
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx Biosciences said on Tuesday its experimental combination cancer drug helped reduce tumors in a mid-stage study in patients with a type of head and neck cancer.
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone Results are most pronounced in HPV+ patients, with cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab alone Inhibrx will expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a potential pathway to accelerated approval Positive results support large expansion opportunities into highly immunogenic tumors and combination with cancer vaccines SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (CPS ≥ 20) metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
Inhibrx Reports Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data. INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.
Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million
SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with Oxford Finance LLC ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to $500.0 million (the "Credit Facility"). The Second Amendment provides for an additional tranche, in an aggregate principal amount of up to $325.0 million in gross proceeds, (i) $100.0 million of which was funded upon execution of the Second Amendment (the "Term C Loan") and (ii) up to an additional $225.0 million of which may be funded in increments of $50.0 million or more upon the Company's request and at the Lenders' sole discretion (the "Term D Loan").
